The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma

Annals of Surgical Oncology

Volumn 20, Issue 3 SUPPL., 2013, Pages

  Abbott, Daniel E ^a   Tzeng, Ching Wei David ^b   Merkow, Ryan P ^c,d   Cantor, Scott B ^b   Chang, George J ^b   Katz, Matthew Harold ^b   Bentrem, David J ^d,e   Bilimoria, Karl Y ^c,d   Crane, Christopher H ^b   Varadhachary, Gauri R ^b   Abbruzzese, James L ^b   Wolff, Robert A ^b   Lee, Jeffrey E ^f   Evans, Douglas B ^f   Fleming, Jason B ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c AMERICAN COLLEGE OF SURGEONS   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e JESSE BROWN VA MEDICAL CENTER   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; ERLOTINIB; GEMCITABINE; ANTINEOPLASTIC AGENT;

ABDOMINAL ABSCESS; ADJUVANT CHEMORADIOTHERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE COST; HUMAN; INOPERABLE CANCER; LAPAROTOMY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS FISTULA; PANCREATICODUODENECTOMY; PNEUMONIA; PREOPERATIVE TREATMENT; QUALITY OF LIFE; REOPERATION; STOMACH EMPTYING; SURGICAL INFECTION; SURVIVAL TIME; TOTAL QUALITY MANAGEMENT; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER STAGING; CHEMORADIOTHERAPY; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; FOLLOW UP; MORTALITY; PANCREAS RESECTION; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; SURVIVAL RATE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FOLLOW-UP STUDIES; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE;

EID: 84892827470     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-2882-0     Document Type: Article

References (34)

1. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-77.
2. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899-903.
3. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-10.
4. Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26: 3503-10.
5. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225:621-33; discussion 33-6.
6. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246:173-80.
7. Bilimoria KY, Bentrem DJ, Ko CY, Tomlinson JS, Stewart AK, Winchester DP, et al. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer. 2007;110:1227-34.
8. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128-37.
9. Lieberman MD, Kilburn H, Lindsey M, Brennan MF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg. 1995;222: 638-45.
10. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-82; discussion 782-4.
11. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496-502.
12. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008;206:833-46; discussion 46-8.
13. Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Fenoglio CJ, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997;15:928-37.
14. Mayo SC, Austin DF, Sheppard BC, Mori M, Shipley DK, Billingsley KG. Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: a population-based analysis. Cancer. 2010;116:2932-40.
15. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-40.
16. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462-7.
17. Talamonti MS, Small W, Jr., Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006;13:150-8.
18. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26: 3487-95.
19. Lowy AM. Neoadjuvant therapy for pancreatic cancer. J Gastrointest Surg. 2008;12:1600-8.
20. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.
21. Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med. 2011;364:2060-5.
22. Ljungman D, Lundholm K, Hyltander A. Cost-utility estimation of surgical treatment of pancreatic carcinoma aimed at cure. World J Surg. 2011;35:662-70.
23. Du W, Touchette D, Vaitkevicius VK, Peters WP, Shields AF. Cost analysis of pancreatic carcinoma treatment. Cancer. 2000; 89:1917-24.
24. Murphy JD, Chang DT, Abelson J, Daly ME, Yeung HN, Nelson LM, et al. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. Cancer. 2012;118:1119-29.
25. Mortenson MM, Ho HS, Bold RJ. An analysis of cost and clinical outcome in palliation for advanced pancreatic cancer. Am J Surg. 2005;190:406-11.
26. Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683-90.
27. Ingraham AM, Richards KE, Hall BL, Ko CY. Quality improvement in surgery: the American College of Surgeons National Surgical Quality Improvement Program approach. Adv Surg. 2010;44:251-67.
28. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138:8-13.
29. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-6.
30. US Department of Health and Human Services. Centers for Medicare and Medicaid Services. http://www.cms.gov. Accessed Mar 22 2011.
31. US Department of Health and Human Services. HCUPnet. http://hcupnet.ahrq. gov/HCUPnet.jsp. Accessed Mar 22 2011
32. West RR, McNabb R, Thompson AG, Sheldon TA, Grimley Evans J. Estimating implied rates of discount in healthcare decision-making. Health Technol Assess. 2003;7:1-60.
33. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244: 10-5.
34. Aloia TA, Lee JE, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR, et al. Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? J AmColl Surg. 2007;204:347-55.